Serum Adenosine Daminase Ativity as a Dagnostic Biomarker in Systemic lupus Eythematosus Patients

Abstract

Background: Adenosine deaminase (ADA) is linked to the development of autoimmune diseases. In order to assess the use of serum ADA activity in diagnosing SLE and assessing disease activity, we examined the serum ADA activity of 70 SLE patients (35 active patients and 35 inactive patients) and 15 healthy controls. Aim: The purpose of this paper is to evaluate the importance of serum ADA activities in identifying SLE and its connection to the activity of the illness. Subjects and Methods: This a randomized prospective efficacy-controlled study conducted on 85 adult Patients (≥ 18 years) with clinically active SLE and clinically non-active SLE and carried at Clinical Pathology Department at Tanta University Hospital. Results: In SLE patients, serum ADA activity was substantially higher in the active patients group than in the inactive patients group when compared to the control group. The best cut-off value for utilizing blood ADA activity to diagnose SLE patients was 12.8 U/L, according to a receiver operating characteristic curve analysis (ROC) (specificity, 100 percent; sensitivity, 100 percent). For lupus patients, serum ADA activity was shown to be more useful than other conventional hematological indicators such as complement C3, complement C4, ANA, and anti-ds DNA. Adenosine deaminase levels were also linked to ESR, blood urea, serum creatinine, Hb levels, Urine albumin/creatinine ratio, anti-nuclear antibody titre, anti-dsDNA antibody, total platelet count, complement C3 and complement C4 levels. Conclusion: Serum ADA activity might be a possible diagnostic sign for SLE, and assessing serum ADA activity can help with illness evaluation and monitoring.